# Doravirine/Islatravir Phase 3 Trial Results

**ID:** TRT-007
**Year:** 2024
**Source:** Merck
**Link:** [https://www.merck.com/news/merck-announces-positive-topline-results-from-the-pivotal-phase-3-trial-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-in-treatment-na/](https://www.merck.com/news/merck-announces-positive-topline-results-from-the-pivotal-phase-3-trial-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-in-treatment-na/)

---

## Abstract

Positive Phase 3 results for once-daily two-drug regimen of doravirine/islatravir in treatment-naive adults.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
